厄贝沙坦; 伊贝沙坦; 2-丁基-3-[4-[2-(1H-四唑-5-基)苯基]苄基]-1,3-二氮杂螺-[4,4]壬-1-烯-4-酮; 2-丁基-3-[邻-1H-5-四唑基苯基]苄基]-1,3-二氮杂螺[4,4]壬-1-烯-4-酮; 2-丁基-3-[[2'-(1H-四唑-5-基)[1,1'-联苯]-4-基]甲基]-1,3-二氮杂螺[4.4]壬-1-烯-4-酮; 安普诺维膜衣锭; 2-丁基-3-[4-[2-(1H-四唑-5-基)苯基]苄基]-1,3-二氮杂螺-[4.4]壬-1-烯-4-酮
2-Butyl-3-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; Irbesartan; MFCD00864464; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; 3-Butyl-2-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-2,4-diazaspiro[4.4]non-3-en-1-one; 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; 2-Butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one; 1,3-diazaspiro4.4non-1-en-4-one, 2-butyl-3-2'-(1H-tetrazol-5-yl)1,1'-biphenyl-4-ylmethyl-; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; Avapro; Irbesartan (GMP); 3-butyl-2-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-2,4-diazaspiro[4.4]non-3-en-1-one; 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE; BMS-186295; AVAPRO; APROVEL; SR-47436; 2-butyl-3-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
-20°C Freezer
水溶性:不溶
1、 摩尔折射率:125.44 2、 摩尔体积(cm3/mol):328.2 3、 等张比容(90.2K):891.5 4、 表面张力(dyne/cm):54.4 5、 极化率(10-24cm3):49.73
1.疏水参数计算参考值(XlogP):4.1 2.氢键供体数量:1 3.氢键受体数量:5 4.可旋转化学键数量:7 5.互变异构体数量:2 6.拓扑分子极性表面积87.1 7.重原子数量:32 8.表面电荷:0 9.复杂度:682 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1
1.性状:从96%乙醇结晶 2.熔点(ºC):180-181℃。